Summit Creek Advisors LLC Invests $3.42 Million in Medpace Holdings, Inc. $MEDP

Summit Creek Advisors LLC bought a new position in Medpace Holdings, Inc. (NASDAQ:MEDP) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 6,449 shares of the company’s stock, valued at approximately $3,415,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in MEDP. Elyxium Wealth LLC bought a new stake in Medpace in the 4th quarter worth approximately $30,000. Allied Private Wealth LLC bought a new position in shares of Medpace during the 2nd quarter valued at approximately $31,000. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in shares of Medpace in the second quarter valued at $34,000. Basecamp Wealth Advisors LLC grew its holdings in shares of Medpace by 187.5% in the first quarter. Basecamp Wealth Advisors LLC now owns 69 shares of the company’s stock valued at $33,000 after purchasing an additional 45 shares in the last quarter. Finally, Quarry LP bought a new stake in Medpace in the third quarter worth $35,000. 77.98% of the stock is owned by institutional investors.

Medpace Stock Down 1.1%

Shares of MEDP opened at $590.30 on Wednesday. The company has a market cap of $16.48 billion, a PE ratio of 34.60, a P/E/G ratio of 2.58 and a beta of 1.15. The business has a fifty day moving average of $541.49 and a 200 day moving average of $491.49. Medpace Holdings, Inc. has a 52-week low of $373.00 and a 52-week high of $677.90.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, topping the consensus estimate of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The company had revenue of $707.33 million during the quarter, compared to analyst estimates of $689.51 million. During the same period in the previous year, the firm earned $3.10 earnings per share. Medpace’s quarterly revenue was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, research analysts anticipate that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Cornelius P. Mccarthy III sold 1,140 shares of the stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $605.37, for a total value of $690,121.80. Following the sale, the director directly owned 12,275 shares of the company’s stock, valued at $7,430,916.75. This represents a 8.50% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO August J. Troendle sold 17,610 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $605.11, for a total transaction of $10,655,987.10. Following the completion of the sale, the chief executive officer directly owned 615,802 shares of the company’s stock, valued at approximately $372,627,948.22. The trade was a 2.78% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 67,195 shares of company stock valued at $37,989,998 in the last quarter. 20.50% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on MEDP shares. Barclays set a $600.00 price target on shares of Medpace in a research note on Thursday, July 23rd. TD Cowen lifted their price objective on shares of Medpace from $419.00 to $492.00 and gave the stock a “hold” rating in a research note on Friday, July 24th. Deutsche Bank Aktiengesellschaft restated a “hold” rating and issued a $535.00 target price on shares of Medpace in a report on Thursday, July 23rd. Mizuho upped their target price on shares of Medpace from $586.00 to $665.00 and gave the company an “outperform” rating in a research report on Friday, July 24th. Finally, Leerink Partners set a $620.00 price target on shares of Medpace in a report on Thursday, July 23rd. Three equities research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $584.18.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.